Literature DB >> 34072277

Management of Intrahepatic Cholangiocarcinoma.

Sudha Kodali1,2, Akshay Shetty1,2, Soumya Shekhar3, David W Victor1,2, Rafik M Ghobrial1,2.   

Abstract

Cholangiocarcinoma is a tumor that arises as a result of differentiation of the cholangiocytes and can develop from anywhere in the biliary tree. Subtypes of cholangiocarcinoma are differentiated based on their location in the biliary tree. If diagnosed early these can be resected, but most cases of intrahepatic cholangiocarcinoma present late in the disease course where surgical resection is not an option. In these patients who are poor candidates for resection, a combination of chemotherapy, locoregional therapies like ablation, transarterial chemo and radioembolization, and in very advanced and metastatic disease, external radiation are the available options. These modalities can improve overall disease-free and progression-free survival chances. In this review, we will discuss the risk factors and clinical presentation of intrahepatic cholangiocarcinoma, diagnosis, available therapeutic options, and future directions for management options.

Entities:  

Keywords:  brachytherapy; chemotherapy; cholangiocarcinoma; intrahepatic; proton beam therapy; resection; short-beam external radiation; transarterial chemoembolization (TACE), Yttrium-90 (Y90), chemotherapy; transplantation

Year:  2021        PMID: 34072277     DOI: 10.3390/jcm10112368

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  87 in total

1.  Genomic spectra of biliary tract cancer.

Authors:  Hiromi Nakamura; Yasuhito Arai; Yasushi Totoki; Tomoki Shirota; Asmaa Elzawahry; Mamoru Kato; Natsuko Hama; Fumie Hosoda; Tomoko Urushidate; Shoko Ohashi; Nobuyoshi Hiraoka; Hidenori Ojima; Kazuaki Shimada; Takuji Okusaka; Tomoo Kosuge; Shinichi Miyagawa; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

Review 2.  Risk factors for cholangiocarcinoma.

Authors:  Gia L Tyson; Hashem B El-Serag
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

3.  Cholangiocarcinoma in sclerosing cholangitis. The role of liver transplantation.

Authors:  A C Stieber; I R Marino; S Iwatsuki; T E Starzl
Journal:  Int Surg       Date:  1989 Jan-Mar

4.  Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis.

Authors:  Siddhartha Yadav; Hao Xie; Irbaz Bin-Riaz; Prabin Sharma; Urshila Durani; Gaurav Goyal; Bijan Borah; Mitesh J Borad; Rory L Smoot; Lewis R Roberts; Ronald S Go; Robert R McWilliams; Amit Mahipal
Journal:  Eur J Surg Oncol       Date:  2019-03-21       Impact factor: 4.424

5.  Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Authors:  Julien Edeline; Meher Benabdelghani; Aurélie Bertaut; Jérôme Watelet; Pascal Hammel; Jean-Paul Joly; Karim Boudjema; Laetitia Fartoux; Karine Bouhier-Leporrier; Jean-Louis Jouve; Roger Faroux; Véronique Guerin-Meyer; Jean-Emmanuel Kurtz; Eric Assénat; Jean-François Seitz; Isabelle Baumgaertner; David Tougeron; Christelle de la Fouchardière; Catherine Lombard-Bohas; Eveline Boucher; Trevor Stanbury; Christophe Louvet; David Malka; Jean-Marc Phelip
Journal:  J Clin Oncol       Date:  2019-02-01       Impact factor: 44.544

6.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

Authors:  Ghassan K Abou-Alfa; Vaibhav Sahai; Antoine Hollebecque; Gina Vaccaro; Davide Melisi; Raed Al-Rajabi; Andrew S Paulson; Mitesh J Borad; David Gallinson; Adrian G Murphy; Do-Youn Oh; Efrat Dotan; Daniel V Catenacci; Eric Van Cutsem; Tao Ji; Christine F Lihou; Huiling Zhen; Luis Féliz; Arndt Vogel
Journal:  Lancet Oncol       Date:  2020-03-20       Impact factor: 41.316

7.  Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.

Authors:  Neil Mehta; Julie Heimbach; Denise M Harnois; Gonzalo Sapisochin; Jennifer L Dodge; David Lee; Justin M Burns; William Sanchez; Paul D Greig; David R Grant; John P Roberts; Francis Y Yao
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

Review 8.  Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.

Authors:  D P Al-Adra; R S Gill; S J Axford; X Shi; N Kneteman; S-S Liau
Journal:  Eur J Surg Oncol       Date:  2014-10-07       Impact factor: 4.424

9.  Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.

Authors:  Farshad Farshidfar; Siyuan Zheng; Marie-Claude Gingras; Yulia Newton; Juliann Shih; A Gordon Robertson; Toshinori Hinoue; Katherine A Hoadley; Ewan A Gibb; Jason Roszik; Kyle R Covington; Chia-Chin Wu; Eve Shinbrot; Nicolas Stransky; Apurva Hegde; Ju Dong Yang; Ed Reznik; Sara Sadeghi; Chandra Sekhar Pedamallu; Akinyemi I Ojesina; Julian M Hess; J Todd Auman; Suhn K Rhie; Reanne Bowlby; Mitesh J Borad; Andrew X Zhu; Josh M Stuart; Chris Sander; Rehan Akbani; Andrew D Cherniack; Vikram Deshpande; Taofic Mounajjed; Wai Chin Foo; Michael S Torbenson; David E Kleiner; Peter W Laird; David A Wheeler; Autumn J McRee; Oliver F Bathe; Jesper B Andersen; Nabeel Bardeesy; Lewis R Roberts; Lawrence N Kwong
Journal:  Cell Rep       Date:  2017-03-14       Impact factor: 9.995

10.  Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative stress.

Authors:  Jianbin Bi; Jia Zhang; Yifan Ren; Zhaoqing Du; Qingshan Li; Yue Wang; Shasha Wei; Lifei Yang; Jingyao Zhang; Chang Liu; Yi Lv; Rongqian Wu
Journal:  Redox Biol       Date:  2018-10-24       Impact factor: 11.799

View more
  2 in total

1.  Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.

Authors:  Xue-Gang Yang; Yan-Yuan Sun; De-Shan Li; Guo-Hui Xu; Xiao-Qi Huang
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

2.  Living Donor Liver Transplantation for Intrahepatic Cholangiocarcinoma.

Authors:  Falk Rauchfuß; Aladdin Ali-Deeb; Oliver Rohland; Felix Dondorf; Michael Ardelt; Utz Settmacher
Journal:  Curr Oncol       Date:  2022-03-13       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.